Evidence map›Paper›PMID 42293250›Full record

ArticleMolecular therapy. Nucleic acids2026

Rational design of hammerhead ribozymes as CD93 silencing tools for vascular diseases.

Cosimo Damiano Perrone, Luisa Raucci, Sara Papini, Gian Marco Tosi, Federico Galvagni, Massimo Olivucci, Danny Incarnato, Maurizio Orlandini

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cosimo Damiano PerroneDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.
Luisa RaucciDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.
Sara PapiniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.
Gian Marco TosiDepartment of Medicine, Surgery and Neuroscience, Ophthalmology Unit, University of Siena, 53100 Siena, Italy.
Federico GalvagniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.
Massimo OlivucciDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.
Danny IncarnatoDepartment of Molecular Genetics, Groningen Biomolecular Sciences and Biotechnology Institute (GBB), University of Groningen, 9747 AG Groningen, the Netherlands.
Maurizio OrlandiniDepartment of Biotechnology, Chemistry and Pharmacy, University of Siena, 53100 Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While targeting angiogenesis represents a key therapeutic strategy in several pathological contexts, it comes with significant challenges associated with therapeutic efficacy and drug resistance. Therefore, developing novel, more effective and durable therapeutic modalities is paramount. We have previously reported that antibody-mediated inhibition of CD93, a vascular endothelial cell surface glycoprotein, can inhibit angiogenesis. Here, we describe a novel strategy to efficiently inhibit CD93 expression in cells, based on the targeted degradation of CD93 mRNA using

Indexed as

age-related macular degenerationangiogenesisCD93endothelial cellshammerhead ribozymeMT: Oligonucleotides: Therapies and Applicationsneovascular diseaseRNA scaffold

Identifiers

PMID42293250
PMCPMC13264038

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.